CA2450076C - Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or a diagnostic agent and pharmaceutical preparations containing said compounds - Google Patents
Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or a diagnostic agent and pharmaceutical preparations containing said compounds Download PDFInfo
- Publication number
- CA2450076C CA2450076C CA2450076A CA2450076A CA2450076C CA 2450076 C CA2450076 C CA 2450076C CA 2450076 A CA2450076 A CA 2450076A CA 2450076 A CA2450076 A CA 2450076A CA 2450076 C CA2450076 C CA 2450076C
- Authority
- CA
- Canada
- Prior art keywords
- carbon atoms
- heteroaryl
- alkyl
- naphthyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 94
- 239000003814 drug Substances 0.000 title claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 title description 10
- 238000000034 method Methods 0.000 title description 9
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 title description 3
- 239000000032 diagnostic agent Substances 0.000 title description 2
- 229940039227 diagnostic agent Drugs 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 12
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 206010003662 Atrial flutter Diseases 0.000 claims abstract description 5
- -1 dimethylamino, sulfamoyl Chemical group 0.000 claims description 213
- 125000004432 carbon atom Chemical group C* 0.000 claims description 203
- 125000001072 heteroaryl group Chemical group 0.000 claims description 151
- 125000000217 alkyl group Chemical group 0.000 claims description 146
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 144
- 229910052801 chlorine Inorganic materials 0.000 claims description 143
- 229910052731 fluorine Inorganic materials 0.000 claims description 143
- 125000001624 naphthyl group Chemical group 0.000 claims description 138
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 136
- 229910052739 hydrogen Inorganic materials 0.000 claims description 131
- 239000001257 hydrogen Substances 0.000 claims description 131
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 120
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 112
- 150000002431 hydrogen Chemical class 0.000 claims description 104
- 125000001424 substituent group Chemical group 0.000 claims description 94
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 77
- 150000003839 salts Chemical class 0.000 claims description 51
- 125000001041 indolyl group Chemical group 0.000 claims description 42
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 42
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 42
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 42
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 42
- 125000004076 pyridyl group Chemical group 0.000 claims description 42
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 42
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 42
- 125000005493 quinolyl group Chemical group 0.000 claims description 42
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 42
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 41
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 41
- 125000003545 alkoxy group Chemical group 0.000 claims description 40
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 32
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 32
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000002541 furyl group Chemical group 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- 229910052740 iodine Inorganic materials 0.000 claims description 13
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 8
- 206010003119 arrhythmia Diseases 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 125000005390 cinnolyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract description 9
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract description 7
- 230000003213 activating effect Effects 0.000 abstract description 6
- 230000003111 delayed effect Effects 0.000 abstract description 6
- 210000002837 heart atrium Anatomy 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 206010003130 Arrhythmia supraventricular Diseases 0.000 abstract description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 4
- 239000011591 potassium Substances 0.000 abstract description 4
- 229910052700 potassium Inorganic materials 0.000 abstract description 4
- 108010042111 Kv1.5 Potassium Channel Proteins 0.000 abstract description 2
- 102000004425 Kv1.5 Potassium Channel Human genes 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 description 77
- 239000000243 solution Substances 0.000 description 44
- 239000002243 precursor Substances 0.000 description 37
- 238000007429 general method Methods 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- WRHNIEDSWVZWKG-UHFFFAOYSA-N 2-(quinolin-8-ylsulfonylamino)benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 WRHNIEDSWVZWKG-UHFFFAOYSA-N 0.000 description 7
- NNJBQTDFDVLWEQ-UHFFFAOYSA-N 2-(sulfonylamino)benzoic acid Chemical class OC(=O)C1=CC=CC=C1N=S(=O)=O NNJBQTDFDVLWEQ-UHFFFAOYSA-N 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108091006146 Channels Proteins 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- JUYUYCIJACTHMK-UHFFFAOYSA-N quinoline-8-sulfonyl chloride Chemical compound C1=CN=C2C(S(=O)(=O)Cl)=CC=CC2=C1 JUYUYCIJACTHMK-UHFFFAOYSA-N 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 150000003335 secondary amines Chemical class 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YLNWJSHBHAFMAT-UHFFFAOYSA-N 1-(5-methylfuran-2-yl)propan-1-amine Chemical compound CCC(N)C1=CC=C(C)O1 YLNWJSHBHAFMAT-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- RSFXOPDETMHJCK-HNNXBMFYSA-N 2-amino-n-[(1s)-1-phenylpropyl]benzamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1N RSFXOPDETMHJCK-HNNXBMFYSA-N 0.000 description 3
- TUNNNFLDZNSBQK-UHFFFAOYSA-N 5-fluoro-2-(quinolin-8-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 TUNNNFLDZNSBQK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000000023 Kugelrohr distillation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- QTUNRTDRPMOQNG-UHFFFAOYSA-N cyclopropyl(phenyl)methanamine;hydron;chloride Chemical compound Cl.C=1C=CC=CC=1C(N)C1CC1 QTUNRTDRPMOQNG-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- VYFOAVADNIHPTR-UHFFFAOYSA-N isatoic anhydride Chemical compound NC1=CC=CC=C1CO VYFOAVADNIHPTR-UHFFFAOYSA-N 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- YKRXJFHSEYGWQY-UHFFFAOYSA-N n-[(1-methylimidazol-2-yl)methyl]-1-phenylmethanamine Chemical compound CN1C=CN=C1CNCC1=CC=CC=C1 YKRXJFHSEYGWQY-UHFFFAOYSA-N 0.000 description 3
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 3
- JQJOGAGLBDBMLU-UHFFFAOYSA-N pyridine-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=N1 JQJOGAGLBDBMLU-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 description 2
- GGUMJDNMKLAOQA-UHFFFAOYSA-N 1-cyclopropyl-1-(6-methoxypyridin-2-yl)-n-phenylmethoxymethanamine Chemical compound COC1=CC=CC(C(NOCC=2C=CC=CC=2)C2CC2)=N1 GGUMJDNMKLAOQA-UHFFFAOYSA-N 0.000 description 2
- PALFZIMHIMRYFF-UHFFFAOYSA-N 1-cyclopropyl-n-pyridin-2-ylmethanimine Chemical compound C1CC1C=NC1=CC=CC=N1 PALFZIMHIMRYFF-UHFFFAOYSA-N 0.000 description 2
- UEBFLTZXUXZPJO-UHFFFAOYSA-N 1-methylimidazole-2-carbaldehyde Chemical compound CN1C=CN=C1C=O UEBFLTZXUXZPJO-UHFFFAOYSA-N 0.000 description 2
- COHYOBKZKMKMIX-UHFFFAOYSA-N 1-phenyl-n-(pyridin-3-ylmethyl)methanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CN=C1 COHYOBKZKMKMIX-UHFFFAOYSA-N 0.000 description 2
- VQGKOCARCUCUMC-UHFFFAOYSA-N 1-pyridin-3-ylpropan-1-amine Chemical compound CCC(N)C1=CC=CN=C1 VQGKOCARCUCUMC-UHFFFAOYSA-N 0.000 description 2
- JOTQNZHTWXIWHJ-UHFFFAOYSA-N 2-(quinolin-8-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 JOTQNZHTWXIWHJ-UHFFFAOYSA-N 0.000 description 2
- SSOCGBMGAODFEA-UHFFFAOYSA-N 2-(sulfonylamino)benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1N=S(=O)=O SSOCGBMGAODFEA-UHFFFAOYSA-N 0.000 description 2
- DLDOXWDYWXYCLC-INIZCTEOSA-N 2-amino-5-methoxy-n-[(1s)-1-phenylpropyl]benzamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C1=CC(OC)=CC=C1N DLDOXWDYWXYCLC-INIZCTEOSA-N 0.000 description 2
- FWRBAPRINZNBIZ-UHFFFAOYSA-N 2-amino-5-methyl-n-[1-(5-methylfuran-2-yl)propyl]benzamide Chemical compound C=1C=C(C)OC=1C(CC)NC(=O)C1=CC(C)=CC=C1N FWRBAPRINZNBIZ-UHFFFAOYSA-N 0.000 description 2
- SZCPTRGBOVXVCA-UHFFFAOYSA-N 2-amino-6-chlorobenzoic acid Chemical compound NC1=CC=CC(Cl)=C1C(O)=O SZCPTRGBOVXVCA-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical compound NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 description 2
- OSMDTSVVCZUJSX-UHFFFAOYSA-N 5-methoxy-2-[(6-methylpyridin-3-yl)sulfonylamino]-n-(1-phenylpropyl)benzamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=C(C)N=C1 OSMDTSVVCZUJSX-UHFFFAOYSA-N 0.000 description 2
- QFPGRDDFLCHSMR-UHFFFAOYSA-N 6-methylpyridine-3-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=N1 QFPGRDDFLCHSMR-UHFFFAOYSA-N 0.000 description 2
- TWKVSHBWJUMVDX-UHFFFAOYSA-N 6-methylpyridine-3-sulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=N1 TWKVSHBWJUMVDX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229940082627 class iii antiarrhythmics Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 2
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 2
- RTQHNAXNVAPCDG-UHFFFAOYSA-N cyclopropyl-(6-methoxypyridin-2-yl)methanamine Chemical compound COC1=CC=CC(C(N)C2CC2)=N1 RTQHNAXNVAPCDG-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 2
- 229960002994 dofetilide Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- KHXUQLMOPQHGCN-NRFANRHFSA-N n-[(1s)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 KHXUQLMOPQHGCN-NRFANRHFSA-N 0.000 description 2
- DDBIXZVIOZQERV-UHFFFAOYSA-N n-[cyclopropyl(phenyl)methyl]formamide Chemical compound C=1C=CC=CC=1C(NC=O)C1CC1 DDBIXZVIOZQERV-UHFFFAOYSA-N 0.000 description 2
- VPHGOUWEVDRSMT-UHFFFAOYSA-N n-benzyl-5-methoxy-n-[(1-methylimidazol-2-yl)methyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(OC)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)N(CC=1C=CC=CC=1)CC1=NC=CN1C VPHGOUWEVDRSMT-UHFFFAOYSA-N 0.000 description 2
- WIKJAZKXHCHEGC-UHFFFAOYSA-N n-cyclopropyl-n-methylpyridin-2-amine;hydrochloride Chemical compound Cl.C=1C=CC=NC=1N(C)C1CC1 WIKJAZKXHCHEGC-UHFFFAOYSA-N 0.000 description 2
- CYTORULYNPVOJI-UHFFFAOYSA-N n-cyclopropyl-n-methylpyridin-3-amine;hydrochloride Chemical compound Cl.C=1C=CN=CC=1N(C)C1CC1 CYTORULYNPVOJI-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- IOLQWLOHKZENDW-UHFFFAOYSA-N phenylisobutylamine Chemical compound CCC(N)CC1=CC=CC=C1 IOLQWLOHKZENDW-UHFFFAOYSA-N 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000036279 refractory period Effects 0.000 description 2
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- WZHRJGWXUCLILI-UHFFFAOYSA-N sulfonylcarbamic acid Chemical compound OC(=O)N=S(=O)=O WZHRJGWXUCLILI-UHFFFAOYSA-N 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 0 *C(c1c(*)c(*)c(*)c(*)c1N(*)S(*)(=O)=O)=O Chemical compound *C(c1c(*)c(*)c(*)c(*)c1N(*)S(*)(=O)=O)=O 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- DOBUSJIVSSJEDA-UHFFFAOYSA-L 1,3-dioxa-2$l^{6}-thia-4-mercuracyclobutane 2,2-dioxide Chemical compound [Hg+2].[O-]S([O-])(=O)=O DOBUSJIVSSJEDA-UHFFFAOYSA-L 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- ZIUBMNMRMGMHGW-UHFFFAOYSA-N 1-cyclopropyl-n-phenylmethoxymethanimine Chemical compound C=1C=CC=CC=1CON=CC1CC1 ZIUBMNMRMGMHGW-UHFFFAOYSA-N 0.000 description 1
- NEPTZDCSJVUYBA-UHFFFAOYSA-N 1-cyclopropyl-n-pyridin-3-ylmethanimine Chemical compound C1CC1C=NC1=CC=CN=C1 NEPTZDCSJVUYBA-UHFFFAOYSA-N 0.000 description 1
- GKDLTXYXODKDEA-UHFFFAOYSA-N 1-phenylbutan-2-one Chemical compound CCC(=O)CC1=CC=CC=C1 GKDLTXYXODKDEA-UHFFFAOYSA-N 0.000 description 1
- WTZFFHKYDKHUSG-UHFFFAOYSA-N 1-phenylprop-2-yn-1-amine Chemical compound C#CC(N)C1=CC=CC=C1 WTZFFHKYDKHUSG-UHFFFAOYSA-N 0.000 description 1
- LEEITMHLSCHFFT-UHFFFAOYSA-N 1-phenylprop-2-yn-1-amine;hydrochloride Chemical compound Cl.C#CC(N)C1=CC=CC=C1 LEEITMHLSCHFFT-UHFFFAOYSA-N 0.000 description 1
- ZHAZHKPVEROFLH-UHFFFAOYSA-N 1-pyridin-2-ylpropan-1-one Chemical compound CCC(=O)C1=CC=CC=N1 ZHAZHKPVEROFLH-UHFFFAOYSA-N 0.000 description 1
- VGFZORUFTNLGLI-UHFFFAOYSA-N 1-pyridin-4-ylpropan-1-amine Chemical compound CCC(N)C1=CC=NC=C1 VGFZORUFTNLGLI-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical class C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 1
- FIWCQRMMVXGAGY-UHFFFAOYSA-N 2-(2,1,3-benzoxadiazol-4-ylsulfonylamino)-n-(1-phenylpropyl)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NON=C3C=CC=2)C=1C(=O)NC(CC)C1=CC=CC=C1 FIWCQRMMVXGAGY-UHFFFAOYSA-N 0.000 description 1
- RAPXTZMERLOQAH-QFIPXVFZSA-N 2-(isoquinolin-5-ylsulfonylamino)-n-[(1s)-1-phenylpropyl]benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=CC=NC=C3C=CC=2)CC)=CC=CC=C1 RAPXTZMERLOQAH-QFIPXVFZSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- ITZHTECUYUADSI-UHFFFAOYSA-N 2-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonylamino]-n-(1-phenylpropyl)benzamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C1=CC=CC=C1NS(=O)(=O)C=1C(C)=NOC=1C ITZHTECUYUADSI-UHFFFAOYSA-N 0.000 description 1
- ZZOLRDNLIGFWNT-NRFANRHFSA-N 2-[(4-chloroquinolin-8-yl)sulfonylamino]-n-[(1s)-1-phenylpropyl]benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC(Cl)=C3C=CC=2)CC)=CC=CC=C1 ZZOLRDNLIGFWNT-NRFANRHFSA-N 0.000 description 1
- UZRZOAHUTCIBBV-UHFFFAOYSA-N 2-[(5-chlorothiophen-2-yl)sulfonylamino]-n-(1-phenylpropyl)benzamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=C(Cl)S1 UZRZOAHUTCIBBV-UHFFFAOYSA-N 0.000 description 1
- LGPVTNAJFDUWLF-UHFFFAOYSA-N 2-amino-4-fluorobenzoic acid Chemical compound NC1=CC(F)=CC=C1C(O)=O LGPVTNAJFDUWLF-UHFFFAOYSA-N 0.000 description 1
- KMODISUYWZPVGV-UHFFFAOYSA-N 2-bromo-6-methoxypyridine Chemical compound COC1=CC=CC(Br)=N1 KMODISUYWZPVGV-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- BCNLCOWQJRGOHX-UHFFFAOYSA-N 2-chloro-6-(quinolin-8-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 BCNLCOWQJRGOHX-UHFFFAOYSA-N 0.000 description 1
- VOTHVVKCDGUCTI-FQEVSTJZSA-N 2-chloro-n-[(1s)-1-phenylpropyl]-6-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2Cl)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 VOTHVVKCDGUCTI-FQEVSTJZSA-N 0.000 description 1
- OXGZSSFUCLZXJH-FQEVSTJZSA-N 2-fluoro-n-[(1s)-1-phenylpropyl]-6-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2F)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 OXGZSSFUCLZXJH-FQEVSTJZSA-N 0.000 description 1
- BXLPZYAVKVFXEO-UHFFFAOYSA-N 2-methyl-5-propionylfuran Chemical compound CCC(=O)C1=CC=C(C)O1 BXLPZYAVKVFXEO-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 150000005341 2-nitrobenzoic acids Chemical class 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- NBHZHTADGZPGAL-UHFFFAOYSA-N 3-chloro-2-(quinolin-8-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 NBHZHTADGZPGAL-UHFFFAOYSA-N 0.000 description 1
- PRLBKHBFMSQDDQ-NRFANRHFSA-N 3-chloro-n-[(1s)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=C(Cl)C=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 PRLBKHBFMSQDDQ-NRFANRHFSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YJOJACJYRQJVBL-UHFFFAOYSA-N 4-chloro-n-(pyrazin-2-ylmethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC2=CC=CN=C2C=1S(=O)(=O)NC1=CC(Cl)=CC=C1C(=O)NCC1=CN=CC=N1 YJOJACJYRQJVBL-UHFFFAOYSA-N 0.000 description 1
- JWJQMFSWWGQCSN-UHFFFAOYSA-N 4-fluoro-2-(quinolin-8-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 JWJQMFSWWGQCSN-UHFFFAOYSA-N 0.000 description 1
- DBVKZIXRKNSBPB-NRFANRHFSA-N 4-fluoro-n-[(1s)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC(F)=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 DBVKZIXRKNSBPB-NRFANRHFSA-N 0.000 description 1
- HERUFEXZDMKCHH-INIZCTEOSA-N 5-chloro-2-[(5-chlorothiophen-2-yl)sulfonylamino]-n-[(1s)-1-phenylpropyl]benzamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C1=CC(Cl)=CC=C1NS(=O)(=O)C1=CC=C(Cl)S1 HERUFEXZDMKCHH-INIZCTEOSA-N 0.000 description 1
- WTGJEYHNRPRLFS-NRFANRHFSA-N 5-chloro-n-[(1s)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=C(Cl)C=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 WTGJEYHNRPRLFS-NRFANRHFSA-N 0.000 description 1
- MIOYYXADVJFREQ-UHFFFAOYSA-N 5-fluoro-n-(1-phenylprop-2-ynyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(F)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C#C)C1=CC=CC=C1 MIOYYXADVJFREQ-UHFFFAOYSA-N 0.000 description 1
- VYUUPUMKBLIKJV-UHFFFAOYSA-N 5-fluoro-n-(1-phenylpropyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(F)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(CC)C1=CC=CC=C1 VYUUPUMKBLIKJV-UHFFFAOYSA-N 0.000 description 1
- WJTYHIRYBCWPQD-UHFFFAOYSA-N 5-fluoro-n-(2-phenoxyethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(F)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NCCOC1=CC=CC=C1 WJTYHIRYBCWPQD-UHFFFAOYSA-N 0.000 description 1
- GFNXMUQMJXRASI-UHFFFAOYSA-N 5-fluoro-n-(2-phenylmethoxyethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(F)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NCCOCC1=CC=CC=C1 GFNXMUQMJXRASI-UHFFFAOYSA-N 0.000 description 1
- VYUUPUMKBLIKJV-OAQYLSRUSA-N 5-fluoro-n-[(1r)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=C(F)C=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 VYUUPUMKBLIKJV-OAQYLSRUSA-N 0.000 description 1
- VYUUPUMKBLIKJV-NRFANRHFSA-N 5-fluoro-n-[(1s)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=C(F)C=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 VYUUPUMKBLIKJV-NRFANRHFSA-N 0.000 description 1
- LFYKTKRJNPCMIH-BOXHHOBZSA-N 5-fluoro-n-[(1s)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide;sodium Chemical compound [Na].C1([C@@H](NC(=O)C=2C(=CC=C(F)C=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 LFYKTKRJNPCMIH-BOXHHOBZSA-N 0.000 description 1
- MFKVNECTRVMJIW-UHFFFAOYSA-N 5-fluoro-n-[1-(5-methylfuran-2-yl)propyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(F)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(CC)C1=CC=C(C)O1 MFKVNECTRVMJIW-UHFFFAOYSA-N 0.000 description 1
- FPQMGQZTBWIHDN-UHFFFAOYSA-N 5-fluoroanthranilic acid Chemical compound NC1=CC=C(F)C=C1C(O)=O FPQMGQZTBWIHDN-UHFFFAOYSA-N 0.000 description 1
- LOVZHFBGNKUCSL-UHFFFAOYSA-N 5-methoxy-n-(1-phenylprop-2-ynyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(OC)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C#C)C1=CC=CC=C1 LOVZHFBGNKUCSL-UHFFFAOYSA-N 0.000 description 1
- BIKZMZYWBXYSFD-UHFFFAOYSA-N 5-methoxy-n-(1-phenylpropyl)-2-(pyridin-2-ylsulfonylamino)benzamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=CC=N1 BIKZMZYWBXYSFD-UHFFFAOYSA-N 0.000 description 1
- MNNDFLZZRUDTSH-UHFFFAOYSA-N 5-methoxy-n-(2-phenylmethoxyethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(OC)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NCCOCC1=CC=CC=C1 MNNDFLZZRUDTSH-UHFFFAOYSA-N 0.000 description 1
- QVKRERYYLIPDOU-QFIPXVFZSA-N 5-methoxy-n-[(1s)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=C(OC)C=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 QVKRERYYLIPDOU-QFIPXVFZSA-N 0.000 description 1
- WAYVZRALCRKXTF-UHFFFAOYSA-N 5-methyl-2-nitrobenzoyl chloride Chemical compound CC1=CC=C([N+]([O-])=O)C(C(Cl)=O)=C1 WAYVZRALCRKXTF-UHFFFAOYSA-N 0.000 description 1
- KTDYNOKUFSRVDV-UHFFFAOYSA-N 5-methyl-n-[1-(5-methylfuran-2-yl)propyl]-2-(pyridin-2-ylsulfonylamino)benzamide Chemical compound C=1C=C(C)OC=1C(CC)NC(=O)C1=CC(C)=CC=C1NS(=O)(=O)C1=CC=CC=N1 KTDYNOKUFSRVDV-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229940123073 Angiotensin antagonist Drugs 0.000 description 1
- 208000032845 Atrial Remodeling Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 238000006434 Ritter amidation reaction Methods 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002369 angiotensin antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000002072 atrial myocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- PJRHFTYXYCVOSJ-UHFFFAOYSA-N cyclopropyl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)C1CC1 PJRHFTYXYCVOSJ-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940082657 digitalis glycosides Drugs 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910000370 mercury sulfate Inorganic materials 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- BMVITMAOJLNORU-UHFFFAOYSA-N n-(1-phenylbutan-2-yl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(CC)CC1=CC=CC=C1 BMVITMAOJLNORU-UHFFFAOYSA-N 0.000 description 1
- GOTDJYMKSNJMCL-UHFFFAOYSA-N n-(1-phenylbutyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(CCC)C1=CC=CC=C1 GOTDJYMKSNJMCL-UHFFFAOYSA-N 0.000 description 1
- KIWPGKWDYLGRGJ-UHFFFAOYSA-N n-(1-phenylprop-2-ynyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C#C)C1=CC=CC=C1 KIWPGKWDYLGRGJ-UHFFFAOYSA-N 0.000 description 1
- ILNQNXDOLDEMED-UHFFFAOYSA-N n-(1-phenylpropyl)-2-(pyridin-2-ylsulfonylamino)benzamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC=N1 ILNQNXDOLDEMED-UHFFFAOYSA-N 0.000 description 1
- GKEOGOUAXAMANM-UHFFFAOYSA-N n-(1-pyridin-3-ylpropyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(CC)C1=CC=CN=C1 GKEOGOUAXAMANM-UHFFFAOYSA-N 0.000 description 1
- LXLPGTAOBJFLNI-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=CC=C3C(NC3C4=CC=CC=C4CC3)=O)=CC=CC2=C1 LXLPGTAOBJFLNI-UHFFFAOYSA-N 0.000 description 1
- IOWHTXVBHMOGKT-UHFFFAOYSA-N n-(2-methoxy-1-phenylethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(COC)C1=CC=CC=C1 IOWHTXVBHMOGKT-UHFFFAOYSA-N 0.000 description 1
- KSQKROIGIPWIMY-UHFFFAOYSA-N n-(2-phenylcyclopropyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC1CC1C1=CC=CC=C1 KSQKROIGIPWIMY-UHFFFAOYSA-N 0.000 description 1
- XTMCMFXLZQKUFK-UHFFFAOYSA-N n-(2-phenylmethoxyethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NCCOCC1=CC=CC=C1 XTMCMFXLZQKUFK-UHFFFAOYSA-N 0.000 description 1
- MZPUKZBZNZFZTQ-UHFFFAOYSA-N n-(2-phenylpropan-2-yl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C)(C)C1=CC=CC=C1 MZPUKZBZNZFZTQ-UHFFFAOYSA-N 0.000 description 1
- QINBXJHYDMZXEJ-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)cyclopropanamine;hydrochloride Chemical compound Cl.C=1C=CC=NC=1CNC1CC1 QINBXJHYDMZXEJ-UHFFFAOYSA-N 0.000 description 1
- BJXLHKJBRORJJJ-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)aniline Chemical compound C=1C=CN=CC=1CNC1=CC=CC=C1 BJXLHKJBRORJJJ-UHFFFAOYSA-N 0.000 description 1
- PEOCADSFXMBKCG-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)cyclopropanamine;hydrochloride Chemical compound Cl.C=1C=CN=CC=1CNC1CC1 PEOCADSFXMBKCG-UHFFFAOYSA-N 0.000 description 1
- RJCBRYIDTCAMRF-MRXNPFEDSA-N n-[(1r)-1-(4-chlorophenyl)ethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C)=CC=C(Cl)C=C1 RJCBRYIDTCAMRF-MRXNPFEDSA-N 0.000 description 1
- WAFSBPJEXXKLES-QGZVFWFLSA-N n-[(1r)-1-(4-methoxyphenyl)ethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1=CC(OC)=CC=C1[C@@H](C)NC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 WAFSBPJEXXKLES-QGZVFWFLSA-N 0.000 description 1
- IQHCGIMGQZQUJU-GOSISDBHSA-N n-[(1r)-1-(4-methylphenyl)ethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C)=CC=C(C)C=C1 IQHCGIMGQZQUJU-GOSISDBHSA-N 0.000 description 1
- SJMPETFNIJYSLO-QGZVFWFLSA-N n-[(1r)-1-phenylethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C)=CC=CC=C1 SJMPETFNIJYSLO-QGZVFWFLSA-N 0.000 description 1
- KHXUQLMOPQHGCN-OAQYLSRUSA-N n-[(1r)-1-phenylpropyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CC)=CC=CC=C1 KHXUQLMOPQHGCN-OAQYLSRUSA-N 0.000 description 1
- VQQZDVDFSLAYJC-NRFANRHFSA-N n-[(1r)-2-hydroxy-1-phenylethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)CO)=CC=CC=C1 VQQZDVDFSLAYJC-NRFANRHFSA-N 0.000 description 1
- VIGRIIJRQJUEIR-KRWDZBQOSA-N n-[(1s)-1-(3-methoxyphenyl)ethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound COC1=CC=CC([C@H](C)NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=C1 VIGRIIJRQJUEIR-KRWDZBQOSA-N 0.000 description 1
- RJCBRYIDTCAMRF-INIZCTEOSA-N n-[(1s)-1-(4-chlorophenyl)ethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C)=CC=C(Cl)C=C1 RJCBRYIDTCAMRF-INIZCTEOSA-N 0.000 description 1
- WAFSBPJEXXKLES-KRWDZBQOSA-N n-[(1s)-1-(4-methoxyphenyl)ethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1=CC(OC)=CC=C1[C@H](C)NC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 WAFSBPJEXXKLES-KRWDZBQOSA-N 0.000 description 1
- IQHCGIMGQZQUJU-SFHVURJKSA-N n-[(1s)-1-(4-methylphenyl)ethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C)=CC=C(C)C=C1 IQHCGIMGQZQUJU-SFHVURJKSA-N 0.000 description 1
- CVZSMFIVUWJYQX-KRWDZBQOSA-N n-[(1s)-1-cyclohexylethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C)CCCCC1 CVZSMFIVUWJYQX-KRWDZBQOSA-N 0.000 description 1
- SJMPETFNIJYSLO-KRWDZBQOSA-N n-[(1s)-1-phenylethyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C1([C@@H](NC(=O)C=2C(=CC=CC=2)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C)=CC=CC=C1 SJMPETFNIJYSLO-KRWDZBQOSA-N 0.000 description 1
- ZINAEQFNKRNWRP-KRWDZBQOSA-N n-[(1s)-1-phenylpropyl]-2-(thiophen-2-ylsulfonylamino)benzamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CS1 ZINAEQFNKRNWRP-KRWDZBQOSA-N 0.000 description 1
- CYCWWQYAFLWRBO-UHFFFAOYSA-N n-[1-(4-chlorophenyl)propyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(CC)C1=CC=C(Cl)C=C1 CYCWWQYAFLWRBO-UHFFFAOYSA-N 0.000 description 1
- LGSBXPLSNAHVAJ-UHFFFAOYSA-N n-[1-(4-fluorophenyl)-2-methylpropan-2-yl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C)(C)CC1=CC=C(F)C=C1 LGSBXPLSNAHVAJ-UHFFFAOYSA-N 0.000 description 1
- IVMTWCLTYANROF-UHFFFAOYSA-N n-[1-(4-fluorophenyl)propyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(CC)C1=CC=C(F)C=C1 IVMTWCLTYANROF-UHFFFAOYSA-N 0.000 description 1
- ORLPQKCLAGZRBD-UHFFFAOYSA-N n-[2-(3,4-dihydro-1h-isoquinoline-2-carbonyl)phenyl]quinoline-8-sulfonamide Chemical compound C1=CN=C2C(S(=O)(=O)NC3=CC=CC=C3C(N3CC4=CC=CC=C4CC3)=O)=CC=CC2=C1 ORLPQKCLAGZRBD-UHFFFAOYSA-N 0.000 description 1
- AVXWSNOPILDQDV-UHFFFAOYSA-N n-[cyclopropyl(phenyl)methyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C=1C=CC=CC=1)C1CC1 AVXWSNOPILDQDV-UHFFFAOYSA-N 0.000 description 1
- DYUUWOWDJOFYKC-UHFFFAOYSA-N n-[cyclopropyl(phenyl)methyl]-5-fluoro-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(F)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C=1C=CC=CC=1)C1CC1 DYUUWOWDJOFYKC-UHFFFAOYSA-N 0.000 description 1
- LAGYCULQKQSHMX-UHFFFAOYSA-N n-[cyclopropyl(phenyl)methyl]-5-methoxy-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C(OC)=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C=1C=CC=CC=1)C1CC1 LAGYCULQKQSHMX-UHFFFAOYSA-N 0.000 description 1
- ZGKBNWNTGFMMOL-UHFFFAOYSA-N n-[phenyl(pyridin-3-yl)methyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC(C=1C=NC=CC=1)C1=CC=CC=C1 ZGKBNWNTGFMMOL-UHFFFAOYSA-N 0.000 description 1
- VUXFOTRZQITDTD-UHFFFAOYSA-N n-benzyl-n-(furan-2-ylmethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)N(CC=1C=CC=CC=1)CC1=CC=CO1 VUXFOTRZQITDTD-UHFFFAOYSA-N 0.000 description 1
- HGCKEQOMTKMGHK-UHFFFAOYSA-N n-benzyl-n-(pyridin-2-ylmethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)N(CC=1N=CC=CC=1)CC1=CC=CC=C1 HGCKEQOMTKMGHK-UHFFFAOYSA-N 0.000 description 1
- PPHSOCROFCONHN-UHFFFAOYSA-N n-benzyl-n-(pyridin-3-ylmethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)N(CC=1C=NC=CC=1)CC1=CC=CC=C1 PPHSOCROFCONHN-UHFFFAOYSA-N 0.000 description 1
- RPEPHYHUHVMOFG-UHFFFAOYSA-N n-benzyl-n-[(1-methylimidazol-2-yl)methyl]-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound CN1C=CN=C1CN(C(=O)C=1C(=CC=CC=1)NS(=O)(=O)C=1C2=NC=CC=C2C=CC=1)CC1=CC=CC=C1 RPEPHYHUHVMOFG-UHFFFAOYSA-N 0.000 description 1
- DYAXICMTNLURRU-UHFFFAOYSA-N n-benzyl-n-cyclopropyl-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)N(C1CC1)CC1=CC=CC=C1 DYAXICMTNLURRU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NMRFEBKWDIFJNE-UHFFFAOYSA-N n-cyclohexyl-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)NC1CCCCC1 NMRFEBKWDIFJNE-UHFFFAOYSA-N 0.000 description 1
- ZEBGMLIVBIDGOZ-UHFFFAOYSA-N n-cyclopropyl-n-(pyridin-3-ylmethyl)-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)N(C1CC1)CC1=CC=CN=C1 ZEBGMLIVBIDGOZ-UHFFFAOYSA-N 0.000 description 1
- GFUKEKROWXOBQW-UHFFFAOYSA-N n-cyclopropyl-n-phenyl-2-(quinolin-8-ylsulfonylamino)benzamide Chemical compound C=1C=CC=C(NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C=1C(=O)N(C=1C=CC=CC=1)C1CC1 GFUKEKROWXOBQW-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YLQBPWQRPIJFPO-UHFFFAOYSA-N n-propylimidazol-1-amine Chemical compound CCCNN1C=CN=C1 YLQBPWQRPIJFPO-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- XAJWHCVLZBSLNC-UHFFFAOYSA-N pyridin-1-ium-2-sulfonyl chloride;chloride Chemical compound Cl.ClS(=O)(=O)C1=CC=CC=N1 XAJWHCVLZBSLNC-UHFFFAOYSA-N 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- CTIRHWCPXYGDGF-HDICACEKSA-N tedisamil Chemical compound [H][C@]12CN(CC3CC3)C[C@]([H])(CN(CC3CC3)C1)C21CCCC1 CTIRHWCPXYGDGF-HDICACEKSA-N 0.000 description 1
- 229960002926 tedisamil Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10128331A DE10128331A1 (de) | 2001-06-12 | 2001-06-12 | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331.8 | 2001-06-12 | ||
| PCT/EP2002/005956 WO2002100825A2 (de) | 2001-06-12 | 2002-05-31 | Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2450076A1 CA2450076A1 (en) | 2002-12-19 |
| CA2450076C true CA2450076C (en) | 2010-11-30 |
Family
ID=7687941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2450076A Expired - Fee Related CA2450076C (en) | 2001-06-12 | 2002-05-31 | Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or a diagnostic agent and pharmaceutical preparations containing said compounds |
Country Status (40)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| US7119112B2 (en) * | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
| AU2003235125A1 (en) * | 2002-04-26 | 2003-11-10 | Ishihara Sangyo Kaisha, Ltd. | Pyridine compounds or salts thereof and herbicides containing the same |
| EP1388535A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| DE10312061A1 (de) * | 2003-03-18 | 2004-09-30 | Aventis Pharma Deutschland Gmbh | Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien |
| GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
| EP1489071A1 (en) * | 2003-06-18 | 2004-12-22 | 4Sc Ag | N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators |
| SG131114A1 (en) | 2003-08-08 | 2007-04-26 | Janssen Pharmaceutica Nv | 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators |
| DE10341233A1 (de) * | 2003-09-08 | 2005-03-24 | Aventis Pharma Deutschland Gmbh | Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien |
| DE102004009931A1 (de) * | 2004-02-26 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
| EA200700717A1 (ru) * | 2004-09-24 | 2007-10-26 | Янссен Фармацевтика Н.В. | Сульфонамиды |
| US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| SG163543A1 (en) * | 2006-04-27 | 2010-08-30 | Sanofi Aventis Deutschland | Inhibitors of the task-1 and task-3 ion channel |
| WO2008124524A2 (en) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Aryl sulfonamide compounds as modulators of the cck2 receptor |
| GB0815784D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815782D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815781D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| CA2765611A1 (en) * | 2009-06-29 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane |
| PT2448582T (pt) | 2009-06-29 | 2017-07-10 | Agios Pharmaceuticals Inc | Compostos e composições terapêuticas |
| WO2011010132A1 (en) * | 2009-07-21 | 2011-01-27 | Astrazeneca Ab | Sustained-release composition comprising compound 600 |
| RU2414893C1 (ru) * | 2009-11-11 | 2011-03-27 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Четвертичное аммониевое производное новокаина, обладающее противоаритмической активностью, и способ его получения |
| FR2967674B1 (fr) | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
| NO3175985T3 (cg-RX-API-DMAC7.html) | 2011-07-01 | 2018-04-28 | ||
| JP2015504923A (ja) | 2012-01-27 | 2015-02-16 | ギリアード サイエンシーズ， インコーポレイテッド | 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法 |
| US9701627B2 (en) * | 2014-06-16 | 2017-07-11 | University Of Maryland, Baltimore | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders |
| KR20200042906A (ko) * | 2017-08-07 | 2020-04-24 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | 신규 안트라닐산계 화합물, 및 이것을 사용한 Pin1 저해제, 염증성 질환의 치료제 및 암의 치료제 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
| US5670504A (en) | 1995-02-23 | 1997-09-23 | Merck & Co. Inc. | 2,6-diaryl pyridazinones with immunosuppressant activity |
| US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
| DK173062B1 (da) | 1996-10-11 | 1999-12-13 | Krueger As I | Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto |
| US5935945A (en) | 1996-10-31 | 1999-08-10 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| US5969017A (en) | 1996-10-31 | 1999-10-19 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| WO2000002851A1 (en) | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| JP2002523451A (ja) * | 1998-09-01 | 2002-07-30 | ブリストル−マイヤーズ スクイブ カンパニー | カリウムチャネル抑制剤および方法 |
| PL352704A1 (en) * | 1999-06-24 | 2003-09-08 | Smithkline Beecham Corporation | Macrophage scavenger receptor antagonists |
| US6531495B1 (en) | 1999-10-02 | 2003-03-11 | Aventis Pharma Deutschland Gmbh | 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
| DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
-
2001
- 2001-06-12 DE DE10128331A patent/DE10128331A1/de not_active Withdrawn
-
2002
- 2002-05-17 PE PE2002000419A patent/PE20021066A1/es not_active Application Discontinuation
- 2002-05-21 OA OA1200300333A patent/OA12631A/fr unknown
- 2002-05-31 CA CA2450076A patent/CA2450076C/en not_active Expired - Fee Related
- 2002-05-31 RU RU2004100302/04A patent/RU2293727C2/ru not_active IP Right Cessation
- 2002-05-31 CZ CZ20033361A patent/CZ20033361A3/cs unknown
- 2002-05-31 SK SK1522-2003A patent/SK15222003A3/sk unknown
- 2002-05-31 DK DK02745333T patent/DK1399423T3/da active
- 2002-05-31 HU HU0400159A patent/HUP0400159A3/hu unknown
- 2002-05-31 RS YU97703A patent/RS97703A/sr unknown
- 2002-05-31 ES ES02745333T patent/ES2295360T3/es not_active Expired - Lifetime
- 2002-05-31 PT PT02745333T patent/PT1399423E/pt unknown
- 2002-05-31 BR BR0210374-5A patent/BR0210374A/pt not_active Application Discontinuation
- 2002-05-31 UA UA2004010206A patent/UA75412C2/uk unknown
- 2002-05-31 NZ NZ530081A patent/NZ530081A/en unknown
- 2002-05-31 AU AU2002316939A patent/AU2002316939B2/en not_active Ceased
- 2002-05-31 KR KR1020037016206A patent/KR100863924B1/ko not_active Expired - Fee Related
- 2002-05-31 PL PL02364371A patent/PL364371A1/xx not_active IP Right Cessation
- 2002-05-31 MX MXPA03010875A patent/MXPA03010875A/es active IP Right Grant
- 2002-05-31 EP EP02745333A patent/EP1399423B9/de not_active Expired - Lifetime
- 2002-05-31 HR HR20031028A patent/HRP20031028A2/hr not_active Application Discontinuation
- 2002-05-31 CN CNB028118502A patent/CN1247544C/zh not_active Expired - Fee Related
- 2002-05-31 EE EEP200300558A patent/EE05196B1/xx not_active IP Right Cessation
- 2002-05-31 WO PCT/EP2002/005956 patent/WO2002100825A2/de not_active Ceased
- 2002-05-31 DE DE50211213T patent/DE50211213D1/de not_active Expired - Lifetime
- 2002-05-31 AT AT02745333T patent/ATE378318T1/de active
- 2002-05-31 JP JP2003503594A patent/JP4422477B2/ja not_active Expired - Fee Related
- 2002-05-31 IL IL15924702A patent/IL159247A0/xx unknown
- 2002-06-10 AR ARP020102178A patent/AR036045A1/es active IP Right Grant
- 2002-06-10 TW TW091112464A patent/TWI304400B/zh not_active IP Right Cessation
- 2002-06-11 MY MYPI20022165A patent/MY138341A/en unknown
- 2002-06-12 US US10/166,595 patent/US6903216B2/en not_active Expired - Lifetime
-
2003
- 2003-07-08 TN TNPCT/EP2002/005956A patent/TNSN03134A1/en unknown
- 2003-10-31 ZA ZA200308520A patent/ZA200308520B/en unknown
- 2003-11-04 CR CR7140A patent/CR7140A/es not_active Application Discontinuation
- 2003-12-03 EC EC2003004883A patent/ECSP034883A/es unknown
- 2003-12-04 BG BG108415A patent/BG108415A/xx unknown
- 2003-12-08 NO NO20035450A patent/NO20035450D0/no not_active Application Discontinuation
- 2003-12-08 IL IL159247A patent/IL159247A/en not_active IP Right Cessation
- 2003-12-10 MA MA27434A patent/MA27037A1/fr unknown
- 2003-12-11 CO CO03108701A patent/CO5540283A2/es not_active Application Discontinuation
-
2005
- 2005-02-08 US US11/052,959 patent/US7235664B2/en not_active Expired - Lifetime
-
2008
- 2008-02-04 CY CY20081100143T patent/CY1107427T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2450076C (en) | Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or a diagnostic agent and pharmaceutical preparations containing said compounds | |
| CA2445341C (en) | Anthranilamides, process for their preparation, their use as antiarrhythmics, and pharmaceutical preparations thereof | |
| RU2278858C2 (ru) | Бис-арильные соединения, фармацевтическая композиция на их основе и применение | |
| EP4019495A1 (en) | Novel compound having cancer metastasis inhibitory activity, preparation method therefor, and pharmaceutical composition for inhibiting cancer metastasis and invasion or treating colorectal cancer, comprising compound | |
| US6087399A (en) | Sulfonamide-substituted compounds, process for their preparation, their use as a medicament or diagnostic, and a medicament comprising them | |
| JPH10182610A (ja) | スルホンアミド−置換された化合物、それらの製法、医薬または診断薬としてのそれらの使用およびそれらを含有する医薬製剤 | |
| CN107056819A (zh) | 一种预防和治疗心肌缺血的药物及其制备方法 | |
| HK1064663B (en) | Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof | |
| CN120965608A (zh) | 一种苯磺酰胺类化合物及其制备方法和应用 | |
| WO2019175464A1 (en) | Compounds useful as inhibitors of sodium-calcium exchanger (ncx) | |
| MXPA98001121A (en) | Compositions replaced with sulfonamide, procedure for its preparation, its employment as a diagnostic medicine or agent as well as a medicine that conti |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160531 |